EXBIO Antibodies

PRODUCT DATA SHEET

1F-518-C025

Monoclonal Antibody to CD263 / TRAIL-R3 Fluorescein (FITC) conjugated (0.025 mg)

Clone: TRAIL-R3-02

Isotype: Mouse IgG1

Specificity: The antibody TRAIL-R3-02 reacts with TRAIL-R3, a 35 kDa GPI-anchored extracellular membrane protein expressed mainly on neutrophils.

Immunogen: TRAIL-R3 (aa 1-280) - hIgGhc fusion protein

Species Reactivity: Human

Preparation: The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC.

Concentration: 0.1 mg/ml

Storage Buffer: The reagent is provided in phosphate buffered saline (PBS) containing 15 mM sodium azide and 0.2% (w/v) high-grade protease free Bovine Serum Albumin (BSA) as a stabilizing agent.

Storage / Stability: Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light.
Do not use after expiration date stamped on vial label.
Short-term exposure to room temperature should not affect the quality of the reagent. However, if reagent is stored under any conditions other than those specified, the conditions must be verified by the user.

Usage: The reagent is designed for Flow Cytometry analysis.
Suggested working concentration is 3 µg/ml. Indicated dilution is recommended starting point for use of this product. Working concentrations should be determined by the investigator.

Expiration: See vial label

Lot Number: See vial label

Background: TRAIL-R3 (CD263, TR3, DcR1, LIT, TRID), expressed mainly on neutrophils, belongs to receptors of TRAIL, a TNF-like membrane cytotoxic protein that induces apoptosis in many tumour cells, but not in normal cells. TRAIL-R3, however, is a GPI-anchored protein that lacks cytoplasmic death domain, thus it is unable to induce apoptosis and serves as a negative regulator of apoptotic signaling by competing for binding of TRAIL with death receptor 5 (DR5).

References:

*Clancy L, Mruk K, Archer K, Woelfel M, Mongkolsapaya J, Screaton G, Lenardo MJ, Chan FK: Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18099-104.
*Sanlioglu AD, Dirice E, Aydin C, Erin N, Koksoy S, Sanlioglu S. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer. 2005 May 25;5(1):54.
*Mérino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O: Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol. 2006 Oct;26(19):7046-55.
*Falschlehner C, Emmerich CH, Gerlach B, Walczak H: TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol. 2007;39(7-8):1462-75.
*Deligezer U, Dalay N: Expression of the TRAIL Receptors in Blood Mononuclear Cells in Leukemia. Pathol Oncol Res. 2007;13(4):290-4.

For laboratory research only, not for drug, diagnostic or other use.

EXBIO Praha | Nad Safinou II 341 | 252 42 Vestec u Prahy | Czech Republic
Tel: +420 261 090 664 | Fax: +420 261 090 660 | orders@exbio.cz | www.exbio.cz